Keyphrases
MHC Class II
100%
Phase II Trial
100%
Metastatic Melanoma
100%
Melanoma Cells
100%
Dendritic Cell Vaccine
100%
DNA Encoding
100%
Gp100
100%
Vaccination
83%
Dendritic Cells
33%
Trial Population
33%
T Lymphocyte Response
33%
Cell Therapy
16%
Epitope
16%
Enzyme-linked Immunosorbent Assay (ELISA)
16%
Cationic Peptides
16%
Non-viral Gene Delivery
16%
Plasmid DNA (pDNA)
16%
Gene Therapy
16%
Interferon-α (IFN-α)
16%
Human Leukocyte Antigen
16%
Biological Effects
16%
ELISPOT
16%
Tumor Regression
16%
Transfection Methods
16%
Disease Response
16%
4-cycle
16%
Therapeutic Vaccine
16%
Antigen Targeting
16%
Peptide Antigen
16%
One-cycle
16%
Effector Responses
16%
Modified Epitope
16%
Online Publication
16%
Autologous Dendritic Cells
16%
Advanced Melanoma
16%
Response Evaluation Criteria in Solid Tumors (RECIST)
16%
Whole Antigen
16%
Medicine and Dentistry
Major Histocompatibility Complex
100%
Dendritic Cell
100%
Dendritic Cell Vaccine
100%
Metastatic Melanoma
100%
Glycoprotein Gp 100
100%
Melan A
100%
Disease
66%
Epitope
66%
T Lymphocyte
66%
Gene Therapy
33%
Biological Activity
33%
Enzyme Linked Immunosorbent Assay
33%
Interferon
33%
Human Leukocyte Antigen
33%
Tumor Regression
33%
Cancer Staging
33%
Melanoma
33%
Tumor Vaccine
33%
Plasmid DNA
33%
Nonviral Gene Delivery System
33%
Immunology and Microbiology
Dendritic Cell
100%
Major Histocompatibility Complex
100%
Dendritic Cell Vaccine
100%
Melan A
100%
T Cell
66%
Epitope
66%
Immunology
33%
Nonviral Gene Delivery System
33%
Plasmid
33%
Biological Activity
33%
Enzyme-Linked Immunosorbent Assay
33%
Human Leukocyte Antigen
33%
interferon
33%
Cancer Staging
33%
Tumor Vaccine
33%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Melanoma
100%
Dendritic Cell Vaccine
100%
Melan A
100%
Glycoprotein Gp 100
100%
Disease
66%
Epitope
66%
Plasmid DNA
33%
Enzyme-Linked Immunosorbent Assay
33%
Melanoma
33%
Tumor Regression
33%
Interferon
33%
Leukocyte Antigen
33%
Cancer Staging
33%
Tumor Vaccine
33%